Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. has demonstrated a robust financial performance, achieving a total revenue of $44 million, which reflects a 15% year-over-year growth in constant currency (CC), slightly improving from the previous quarter's growth of 14% CC. The company is experiencing a rise in gene therapy programs across all stages, fueled by advancements in oncology and rare disease therapies, contributing to an upward trend in the number of approved therapies and those in development. Overall, the growth in commercial revenue and clinical trial activity, supported by increasing market acceptance of cell and gene therapies, positions CryoPort favorably for continued expansion in the life sciences sector.

Bears say

CryoPort Inc. is experiencing a decline in funding for startups within its sector, which may hinder future growth opportunities, particularly as revenue from both the Life Sciences Services and Life Sciences Products segments shows signs of slowing growth. Although Life Sciences Services reported a year-over-year revenue increase of 16% to $24 million, this growth rate has decreased from 21% in the prior quarter, and adjusted EBITDA margin remains negative at (1.5%), underperforming consensus expectations. Furthermore, a bear case scenario suggests that anticipated slowdowns in cell and gene therapy approvals, coupled with reduced demand for MVE freezers and lowered earnings expectations for 2026, indicate significant challenges to the company's revenue potential and profitability moving forward.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Jan 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.